



9 Ogos 2021
9 August 2021
P.U. (A) 332

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT
GAZETTE*

PERINTAH RACUN (PINDAAN SENARAI RACUN)
2021

POISONS (AMENDMENT OF POISONS LIST) ORDER 2021

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2021

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2021**.

Pindaan Jadual Pertama

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) di bawah “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”, dengan menggantikan butiran “Colchicine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Colchicine	Veterinary preparations for food-producing animals	-	All preparations unless in Group A";			

(ii) dengan memasukkan selepas butiran "Alogliptin" dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Alpelisib	-	All preparations";				

- (iii) dengan memasukkan selepas butiran “Alphadolone acetate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Alpha-Phenylacetoacetamide (APAA)”	-	-	-	-	All preparations”;	

- (iv) dengan memasukkan selepas butiran “Alpha-Phenylacetonitrile (APAAN)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Alpha-Pyrrolidinohexanophenone (Alpha-PHP, PV-7)”	-	All preparations”;				

- (v) dengan memasukkan selepas butiran “2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA) (DD)	-	All preparations				
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide (ADB-FUBINACA) (DD)	-	All preparations”;				

(vi) dengan memasukkan selepas butiran “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (DD)” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide (AB-FUBINACA)	-	All preparations”;				

(vii) dengan memasukkan selepas butiran “Cabergoline” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cabozantinib	-	All preparations”;				

(viii) dengan menggantikan butiran “Chlorpromazine” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Chlorpromazine	Veterinary preparations for food-producing animals	All preparations unless in Group A”;				

(ix) dengan menggantikan butiran “Clioquinol and other halogenated hydroxyquinoline compound” dengan butiran “Clioquinol and other halogenated hydroxyquinoline compound except halquinol”;

- (x) dengan memasukkan selepas butiran “Cucurbitacin; its derivatives” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) (DD)	-	All preparations”;				

- (xi) dengan memasukkan selepas butiran “Daclatasvir” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dacomitinib	-	All preparations”;				

(xii) dengan menggantikan butiran “Dapsone” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dapsone	Veterinary preparations for food-producing animals	All preparations unless in Group A”;				

(xiii) dengan memasukkan selepas butiran “Dimethoxybromoamphetamine (DOB) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2,5-Dimethoxy-4-chloroamphetamine (DOC) (DD)	-	All preparations”;				

(xiv) dengan memasukkan selepas butiran “Ectylurea” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Edoxaban	-	All preparations”;				

(xv) dengan memasukkan selepas butiran “N-Ethylamphetamine; its salts” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Ethylhexedrone (NEH, Hexen, Ethyl- Hex)	-	All preparations”;				

(xvi) dengan memasukkan selepas butiran “N-ethyl MDA (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Ethylnorpentylone (Ephylone) (DD)	-	All preparations”;				

(xvii) dengan memasukkan selepas butiran “Etidronate disodium” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Etizolam	-	All preparations”;				

(xviii) dengan memasukkan selepas butiran “Fampridine” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Favipiravir	-	All preparations”;				

(xix) dengan memasukkan selepas butiran “4-Fluoroamphetamine (4-FA) (DD)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-{{1-(4-Fluorobutyl)-1H-indazole-3-carbonyl}amino}-3,3-dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB, 4F-MDMB-BUTINACA)	-	All preparations”;				

(xx) dengan memasukkan selepas butiran “Halothane” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Halquinol	All preparations unless in Group B	Veterinary preparations”;				

(xxi) dengan memasukkan selepas butiran “2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl alpha-phenylacetoacetate (MAPA)	-	-	-	-	All preparations”;	

(xxii) dengan memasukkan selepas butiran “Methyl 2-([1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl)amino)-3-methylbutanoate (5F-AMB)” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl (2S)-2-([1-(5- fluoropentyl)-1H-indole-3-carbonyl]amino)-3,3-dimethylbutanoate (5F-MDMB-PICA)	-	All preparations				
Methyl (2S)-2-([1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl]amino)-3-methylbutanoate (FUB-AMB) (DD)	-	All preparations				
3,4-MDP-2-P Methyl glycidate (PMK glycidate)	-	-	-	-	All preparations	
3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)	-	-	-	-	All preparations”;	

(xxiii) dengan menggantikan butiran “Metronidazole” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Metronidazole	Veterinary preparations for food-producing animals	All preparations unless in Group A”;					

(xxiv) dengan menggantikan perkataan “Monoclonal antibody; includes the followings:” dengan perkataan “Monoclonal antibody; includes the following:”;

(xxv) di bawah “Monoclonal antibody; includes the following:”—

(A) dengan memasukkan selepas butiran “Evolocumab” butiran “Galcanzumab”; dan

(B) dengan memasukkan selepas butiran “Pertuzumab” butiran “Polatuzumab vedotin”;

(xxvi) di bawah “Narcotic substances; the following:”—

- (A) dengan memasukkan selepas butiran “(DD) Codoxime” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Crotonylfentanyl	-	All preparations”;					

- (B) dengan memasukkan selepas butiran “(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Cyclopropylfentanyl	-	All preparations”;					

(C) dengan memasukkan selepas butiran “(DD) Methadone-Intermediate” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Methoxyacetylfentanyl	-	All preparations”;				

(D) dengan memasukkan selepas butiran “(DD) Opium” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Orthofluorofentanyl	-	All preparations”;				

- (E) dengan memasukkan selepas butiran “(DD) Oxymorphone” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Parafluorobutyrylfentanyl	-	All preparations”; dan				

- (F) dengan memasukkan selepas butiran “(DD) Trimeperidine” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Valeryl-fentanyl	-	All preparations”;				

(xxvii) dengan memasukkan selepas butiran “Omeprazole” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Omidenepag	-	All preparations”;				

(xxviii) dengan menggantikan butiran “Profafenone; its salts” dengan butiran “Propafenone; its salts”;

(xxix) dengan memasukkan selepas butiran “Rufinamide” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Rurioctocog alfa pegol	-	All preparations”;				

(xxx) dengan memasukkan selepas butiran “Umeclidinium” dan butir-butir yang berhubungan dengannya butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Upadacitinib	-	All preparations”; dan				

(xxxi) dengan menggantikan butiran “Vancomycin” dan butir-butir yang berhubungan dengannya dengan butiran yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vancomycin	Veterinary preparations for food-producing animals	All preparations unless in Group A or Group D	-	Preparations for laboratory use”; dan		

(b) dalam Lampiran kepada Senarai Racun—

(i) dalam senarai “**Amoebicides:**” —

(A) dengan menggantikan butiran “Clioquinol and other halogenated hydroxyquinoline compounds” dengan butiran “Clioquinol and other halogenated hydroxyquinoline compounds except halquinol”; dan

(B) dengan memasukkan selepas butiran “Emetine” butiran “Halquinol”;

(ii) dalam senarai “**Analeptics and Central Stimulants:**” —

(A) dengan memasukkan sebelum butiran “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) (DD)” butiran “N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA) (DD)”;

(B) dengan memasukkan selepas butiran “Dimethoxybromoamphetamine (DOB) (DD)” butiran “2,5-Dimethoxy-4-chloroamphetamine (DOC) (DD)”;

(C) dengan memasukkan selepas butiran “N-Ethylamphetamine; its salts” butiran “N-Ethylhexedrone (NEH, Hexen, Ethyl-Hex)”;

- (D) dengan memasukkan selepas butiran “N-Ethyl MDA (DD)” butiran “N-Ethylnorpentylone (Ephylone) (DD)”;
- (iii) dalam senarai “**Analgesics including antipyretic and anti-inflammatory agents:**” —
- (A) dengan memasukkan selepas butiran “Amidopyrine; its salts” butiran “N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide (ADB-FUBINACA) (DD)”;
- (B) dengan memasukkan selepas butiran “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone(XLR-11)” butiran “Galcanezumab”;
- (iv) dalam senarai “**Antineoplastic agents and Immunosuppressants:**”—
- (A) dengan memasukkan selepas butiran “Alemtuzumab” butiran “Alpelisib”;
- (B) dengan memasukkan selepas butiran “Cabazitaxel” butiran “Cabozantinib”;
- (C) dengan memasukkan selepas butiran “Dacliximab” butiran “Dacomitinib”;
- (D) dengan memasukkan selepas butiran “Pirfenidone” butiran “Polatuzumab vedotin”; dan
- (E) dengan memasukkan selepas butiran “Trofosfamide” butiran “Upadacitinib”;

- (v) dalam senarai “**Antiviral agents:**” dengan memasukkan selepas butiran “Famciclovir” butiran “Favipiravir”;
- (vi) dalam senarai “**Cardio drugs:**” dengan menggantikan butiran “Profafenone; its salts” dengan butiran “Propafenone; its salts”;
- (vii) dalam senarai “**Industrial and laboratory poisons:**”—
- (A) dengan memasukkan selepas butiran “Acetyl chloride” butiran “Alpha-Phenylacetoacetamide (APAA)”;
- (B) dengan memasukkan selepas butiran “Lysergic acid; its salts” butiran berikut:
- “Methyl alpha-phenylacetoacetate (MAPA)
- 3,4-MDP-2-P Methyl glycidate (PMK glycidate)
- 3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)”;
- (viii) dalam senarai “**Narcotics:**”—
- (A) dengan memasukkan selepas butiran “(DD) Codoxime” butiran “(DD) Crotonylfentanyl”;

- (B) dengan memasukkan selepas butiran “(DD) 1-Cyclohexyl-4-(1,2- diphenylethyl)piperazine (MT-45)” butiran “(DD) Cyclopropylfentanyl”;
 - (C) dengan memasukkan selepas butiran “(DD) Methadone-Intermediate” butiran “(DD) Methoxyacetylfentanyl”;
 - (D) dengan memasukkan selepas butiran “(DD) Opium” butiran “(DD) Orthofluorofentanyl”;
 - (E) dengan memasukkan selepas butiran “(DD) Oxymorphone” butiran “(DD) Parafluorobutyrylfentanyl”; dan
 - (F) dengan memasukkan selepas butiran “(DD) Trimeperidine” butiran “(DD) Valerylfentanyl”;
- (ix) dalam senarai “**Thrombolytics/Fibrinolytics:**” dengan memasukkan selepas butiran “Drotrecogin alfa (Recombinant human activated Protein C)” butiran “Edoxaban”;
- (x) dalam senarai “**Tranquillisers:**” dengan memasukkan selepas butiran “Emlcamate” butiran “Etizolam”; dan
- (xi) dalam senarai “**Miscellaneous:**”—
- (A) dengan menggantikan butiran “Allergens (in test kits)” dengan butiran “Allergens”;

- (B) dengan memasukkan selepas butiran “Allergens” butiran “Alpha-Pyrrolidinohexanophenone (Alpha-PHP, PV-7)”;
- (C) dengan memasukkan selepas butiran “Amino acids, unless specified elsewhere in the List” butiran “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl] indazole-3-carboxamide (AB-FUBINACA)”;
- (D) dengan memasukkan selepas butiran “Cucurbitacin; its derivatives” butiran “1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) (DD)”;
- (E) dengan memasukkan selepas butiran “Fluorides, alkali; organofluorides” butiran “2-{{1-(4-Fluorobutyl)-1H-indazole-3-carbonyl}amino}-3,3-dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB, 4F-MDMB-BUTINACA)”;
- (F) dengan memasukkan selepas butiran “3,4 -Methylenedioxypropylvalerone (MDPV)” butiran berikut:
- “Methyl (2S)-2-{{1-(5-fluoropentyl)-1H-indole-3-carbonyl}amino}-3,3-dimethylbutanoate (5F-MDMB-PICA)
- Methyl (2S)-2-{{1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino}-3-methylbutanoate (FUB-AMB) (DD)”;
- (G) dengan memasukkan selepas butiran “Omalizumab” butiran “Omidenepag”; dan

(H) dengan memasukkan selepas butiran “Rosuvastatin” butiran “Rurioctocog alfa pegol”.

Dibuat 6 Julai 2021

[KKM.R.600-1/1/56; PN(PU2)172/XIX]

DATO' SRI DR. ADHAM BIN BABA
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2021

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2021**.

Amendment of First Schedule

2. The Poisons Act 1952 is amended in the First Schedule —

(a) in the Poison List—

- (i) under “Alkaloids; the following: their salts, simple or complex; their quaternary compounds:”, by substituting for the item “Colchicine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Colchicine	Veterinary preparations for food-producing animals	-	All preparations unless in Group A";			

(ii) by inserting after the item "Alogliptin" and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Alpelisib	-	All preparations";				

(iii) by inserting after the item “Alphadolone acetate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Alpha-Phenylacetoacetamide (APAA)”	-	-	-	-	All preparations”;	

(iv) by inserting after the item “Alpha-Phenylacetonitrile (APAAN)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Alpha-Pyrrolidinohexanophenone (Alpha-PHP, PV-7)”	-	All preparations”;				

(v) by inserting after the item “2-Amino-1-(2, 5-dimethoxy-4-methyl) phenylpropane (DD)” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA) (DD)	-	All preparations				
N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide (ADB-FUBINACA) (DD)	-	All preparations”;				

(vi) by inserting after the item “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide (AB-FUBINACA)	-	All preparations”;				

(vii) by inserting after the item “Cabergoline” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Cabozantinib	-	All preparations”;				

(viii) by substituting for the item “Chlorpromazine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Chlorpromazine	Veterinary preparations for food-producing animals	All preparations unless in Group A";				

- (ix) by substituting for the item "Clioquinol and other halogenated hydroxyquinoline compound" the item "Clioquinol and other halogenated hydroxyquinoline compound except halquinol";
- (x) by inserting after the item "Cucurbitacin; its derivatives" and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) (DD)	-	All preparations";				

(xi) by inserting after the item “Daclatasvir” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dacomitinib	-	All preparations”;				

(xii) by substituting for the item “Dapsone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Dapsone	Veterinary preparations for food-producing animals	All preparations unless in Group A”;				

(xiii) by inserting after the item “Dimethoxybromoamphetamine (DOB) (DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2,5-Dimethoxy-4-chloroamphetamine (DOC) (DD)	-	All preparations”;				

(xiv) by inserting after the item “Ectylurea” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Edoxaban	-	All preparations”;				

(xv) by inserting after the item “N-Ethylamphetamine; its salts” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Ethylhexedrone (NEH, Hexen, Ethyl-Hex)	-	All preparations”;				

(xvi) by inserting after the item “N-ethyl MDA (DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“N-Ethylnorpentylone (Ephylone) (DD)	-	All preparations”;				

(xvii) by inserting after the item “Etidronate disodium” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Etizolam	-	All preparations”;				

(xviii) by inserting after the item “Fampridine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Favipiravir	-	All preparations”;				

(xix) by inserting after the item “4-Fluoroamphetamine (4-FA) (DD)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“2-[[1-(4-Fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB, 4F-MDMB-BUTINACA)	-	All preparations”;				

(xx) by inserting after the item “Halothane” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Halquinol	All preparations unless in Group B	Veterinary preparations”;				

(xxi) by inserting after the item “2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl alpha-phenylacetoacetate (MAPA)”	-	-	-	-	All preparations”;	

(xxii) by inserting after the item “Methyl 2-([1-(5-fluoropentyl)-1H-indazol-3-yl] carbonyl)amino)-3- methylbutanoate (5F-AMB)” and the particulars relating to it the following items:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Methyl (2S)-2-([1-(5- fluoropentyl)-1H-indole-3-carbonyl]amino)-3,3-dimethylbutanoate (5F-MDMB-PICA)”	-		All preparations			

Methyl (2S)-2-({1-[4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB) (DD)	-					All preparations
3,4-MDP-2-P Methyl glycidate (PMK glycidate)	-	-	-	-		All preparations
3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)	-	-	-	-		All preparations”;

(xxiii) by substituting for the item “Metronidazole” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Metronidazole	Veterinary preparations for food-producing animals	All preparations unless in Group A”;				

(xxiv) by substituting for the words “Monoclonal antibody; includes the followings;” the words “Monoclonal antibody; includes the following:”;

(xxv) under “Monoclonal antibodies; includes the following:”—

(A) by inserting after the item “Evolocumab” the item “Galcanezumab”; and

(B) by inserting after the item “Pertuzumab” the item “Polatuzumab vedotin”;

(xxvi) under “Narcotic substances; the following:”—

(A) by inserting after the item “(DD) Codoxime” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“(DD) Crotonylfentanyl	-	“All preparations”;					

(B) by inserting after the item “(DD) 1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Cyclopropylfentanyl	-	All preparations”;				

(C) by inserting after the item “(DD) Methadone -Intermediate” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Methoxyacetylfentanyl	-	All preparations”;				

(D) by inserting after the item “(DD) Opium” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Orthofluorofentanyl	-	All preparations”;				

(E) by inserting after the item “(DD) Oxymorphone” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Parafluorobutyrylfentanyl	-	All preparations”;				
		and				

(F) by inserting after the item “(DD) Trimeperidine” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“(DD) Valeryl fentanyl	-	All preparations”;				

(xxvii) by inserting after the item “Omeprazole” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Omidenepag	-	All preparations”;				

(xxviii) by substituting for the item “Profafenone; its salts” the item “Propafenone; its salts”;

(xxix) by inserting after the item “Rufinamide” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Rurioctocog alfa pegol	-	All preparations”;				

(xxx) by inserting after the item “Umeclidinium” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Upadacitinib	-	All preparations”;				
		and				

(xxxi) by substituting for the item “Vancomycin” and the particulars relating to it the following item:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Vancomycin	Veterinary preparations for food-producing animals	All preparations unless in Group A or Group D	-	Preparations for laboratory use”; and		

(b) in the Appendix to the Poisons List—

(i) in the list of “**Amoebicides:**”—

(A) by substituting for the item “Clioquinol and other halogenated hydroxyquinoline compounds” the item “Clioquinol and other halogenated hydroxyquinoline compounds except halquinol”; and

(B) by inserting after the item “Emetine” the item “Halquinol”;

(ii) in the list of “**Analeptics and Central Stimulants:**”—

- (A) by inserting after the item “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) (DD)” the item “N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA, MAB-CHMINACA) (DD)”;
 - (B) by inserting after the item “Dimethoxybromoamphetamine (DOB) (DD)” the item “2,5-Dimethoxy-4-chloroamphetamine (DOC) (DD)”;
 - (C) by inserting after the item “N-Ethylamphetamine; its salts” the item “N-Ethylhexedrone (NEH, Hexen, Ethyl-Hex)”;
 - (D) by inserting after the item “N-Ethyl MDA (DD)” the item “N-Ethylnorpentylone (Ephylone) (DD)”;
- (iii) in the list of “**Analgesics including antipyretic and anti-inflammatory agents:**”—
- (A) by inserting after the item “Amidopyrine; its salts” the item “N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide (ADB-FUBINACA) (DD)”;
 - (B) by inserting after the item “[1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone(XLR-11)” the item “Galcanezumab”;

- (iv) in the list of “**Antineoplastic agents and Immunosuppressants:**”—
 - (A) by inserting after the item “Alemtuzumab” the item “Alpelisib”;
 - (B) by inserting after the item “Cabazitaxel” the item “Cabozantinib”;
 - (C) by inserting after the item “Dacliximab” the item “Dacomitinib”;
 - (D) by inserting after the item “Pirfenidone” the item “Polatuzumab vedotin”; and
 - (E) by inserting after the item “Trofosfamide” the item “Upadacitinib”;
- (v) in the list of “**Antiviral agents:**” by inserting after the item “Famciclovir” the item “Favipiravir”;
- (vi) in the list of “**Cardio drugs:**” by substituting for the item “Profafenone; it salts” the item “Propafenone; it salts”;
- (vii) in the list of “**Industrial and laboratory poisons:**” —
 - (A) by inserting after the item “Acetyl chloride” the item “Alpha-Phenylacetoacetamide (APAA)”;

(B) by inserting after the item “Lysergic acid; its salts” the following items:

“Methyl alpha-phenylacetoacetate (MAPA)

3,4-MDP-2-P Methyl glycidate (PMK glycidate)

3,4-MDP-2-P Methyl glycidic acid (PMK glycidic acid)”;

(viii) in the list of “**Narcotics:**” —

(A) by inserting after the item “(DD) Codoxime” the item “(DD) Crotonylfentanyl”;

(B) by inserting after the item “(DD) 1-Cyclohexyl-4-(1,2- diphenylethyl)piperazine (MT-45)” the item “(DD) Cyclopropylfentanyl”;

(C) by inserting after the item “(DD) Methadone-Intermediate” the item “(DD) Methoxyacetylfentanyl”;

(D) by inserting after the item “(DD) Opium” the item “(DD) Orthofluorofentanyl”;

(E) by inserting after the item “(DD) Oxymorphone” the item “(DD) Parafluorobutyrylfentanyl”; and

- (F) by inserting after the item “(DD) Trimeperidine” the item “(DD) Valerylfeentanyl”;
- (ix) in the list of “**Thrombolytics/Fibrinolytics:**”, by inserting after the item “Drotrecogin alfa (Recombinant human activated Protein C)” the item “Edoxaban”;
- (x) in the list of “**Tranquillisers:**” by inserting after the item “Emylcamate” the item “Etizolam”; and
- (xi) in the list of “**Miscellaneous:**”—
- (A) by substituting for the item “Allergens (in test kits)” the item “Allergens”;
- (B) by inserting after the item “Allergens” the item “Alpha-Pyrrolidinohexanophenone (Alpha-PHP, PV-7)”;
- (C) by inserting after the item “Amino acids, unless specified elsewhere in the List” the item “N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide (AB-FUBINACA)”;
- (D) by inserting after the item “Cucurbitacin; its derivatives” the item “1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) (DD)”;
- (E) by inserting after the item “Fluorides, alkali; organofluorides” the item “2-{{1-(4-Fluorobutyl)-1H-indazole-3-carbonyl}amino}-3,3-dimethylbutanoate (4-F-MDMB-BINACA, 4F-ADB, 4F-MDMB-BUTINACA)”;

(F) by inserting after the item “3,4 -Methylenedioxypropylvalerone (MDPV)” the following items:

“Methyl (2S)-2-{{1-(5-fluoropentyl)-1H-indole-3-carbonyl}amino}-3,3-dimethylbutanoate (5F-MDMB-PICA)

Methyl (2S)-2-{{1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (FUB-AMB
(DD)”;

(G) by inserting after the item “Omalizumab” the item “Omidenepag”; and

(H) by inserting after the item “Rosuvastatin” the item “Rurioctocog alfa pegol”.

Made 6 July 2021

[KKM.R.600-1/1/56; PN(PU2)172/XIX]

DATO' SRI DR. ADHAM BIN BABA
Minister of Health